A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in
Patients with Locally Advanced Unresectable/Metastatic Solid Tumours to determine the safety
and tolerability of RC118, including the maximum tolerated dose (MTD)/maximum administered
dose (MAD), and to define the recommended Phase II dose (RP2D).